Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Cash: 2020-2024

Historic Change in Cash for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $141.5 million.

  • Prime Medicine's Change in Cash fell 72.05% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 162.95%. This contributed to the annual value of $141.5 million for FY2024, which is 196.87% up from last year.
  • Latest data reveals that Prime Medicine reported Change in Cash of $141.5 million as of FY2024, which was up 196.87% from -$146.0 million recorded in FY2023.
  • Prime Medicine's Change in Cash's 5-year high stood at $161.6 million during FY2021, with a 5-year trough of -$146.0 million in FY2023.
  • For the 3-year period, Prime Medicine's Change in Cash averaged around -$669,000, with its median value being $2.6 million (2022).
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 470.35% in 2021, then tumbled by 5,780.51% in 2023.
  • Yearly analysis of 5 years shows Prime Medicine's Change in Cash stood at $28.3 million in 2020, then skyrocketed by 470.35% to $161.6 million in 2021, then crashed by 98.41% to $2.6 million in 2022, then crashed by 5,780.51% to -$146.0 million in 2023, then soared by 196.87% to $141.5 million in 2024.